Nobody Understands Peptides

Name: Nobody Understands Peptides
Creator: Hillary Lin, MD
Published: 2026-07-31T09:00:00-04:00
Keywords: peptides, peptide therapy, are peptides safe, peptide evidence, BPC-157, TB-500, MOTS-c, Semax, Epitalon, AOD-9604, compounded peptides, research peptides, longevity peptides, semaglutide peptide, retatrutide, Peptides, Medications, Longevity Medicine, Evidence Literacy

In July 2026, PCAC supported six peptide families and voted against DSIP/emideltide. The votes were advisory. FDA did not approve a drug or issue a final 503A rule, and the human-evidence grades did not change. Peptides range from FDA-approved drugs to research powders with no human evidence, so assess the exact molecule, form, claim, route, evidence, regulatory status, and source.

Hillary Lin, MD·Reviewed July 31, 2026·4 min read

Molecule type

Peptide describes a short chain of amino acids. It includes established drugs such as insulin and semaglutide as well as research powders with no human trials.

July PCAC vote

PCAC supported six peptide families and voted against DSIP/emideltide. FDA did not approve a drug or issue a final 503A rule.

Claim-specific grade

The votes did not change the human evidence. Each grade applies to one molecule, form, claim, route, and population.

Peptide molecules organized by human evidence, regulatory status, route, and source risk.

The Peptide Decoder

Each row grades one peptide for one claim. The same molecule can have strong evidence for one indication and little evidence for another.

I grade the claim first and list access separately.

FDA approval, 503A or 503B compounding, clinical-trial access, and gray-market supply mean different things. We list them separately.

peptide-decoder-v0-4Updated 2026-07-3122 source-checked rows

In July, PCAC supported six peptide families and voted against DSIP/emideltide. The votes were advisory. FDA did not approve a drug or issue a final 503A rule. Read the vote record.

Peptide molecules arranged by human evidence and source risk.

Evidence grades

Grades describe the claim, not the molecule as a whole.

A: FDA has approved the exact use, or guidelines and large, replicated human RCTs support it with meaningful clinical endpoints.
B: Multiple credible controlled human trials show consistent benefit and an acceptable safety signal, but regulators may not have approved the exact use.
C: Human studies exist, but they are small, old, regional, unreplicated, inconsistent, or below FDA and EMA standards.
D: Evidence comes mostly from mechanisms, cells, animals, biomarkers, observational data, tiny uncontrolled pilots, or related drugs.
F: Public claims substantially outrun credible human evidence for that use.
N/A: This row explains regulation or product quality rather than efficacy.

Claim: what the peptide is supposed to do
Evidence: human results for that exact claim
Access: FDA approval, compounding, trials, or gray market
First move: what I would consider first

Start here

Start with the rows that separate approved drugs, repair claims, investigational drugs, salt forms, and research vials.

Skip to the full table

Semaglutide / tirzepatide

Summary anchor: weight loss, diabetes, cardiometabolic risk

Semaglutide and tirzepatide have FDA-approved uses backed by large human trials. That evidence applies to the indicated drug and product, not every peptide vial.

strong human evidence

FDA-approved branded; lower risk

BPC-157

Injury recovery, tendon/ligament healing, joint pain, gut repair

BPC-157 has animal data and one tiny uncontrolled human series; that cannot guide recovery or return to sport.

mostly mechanism

503A review only; highest risk

TB-500 / thymosin beta-4 fragment

Injury recovery, tendon/muscle healing, Wolverine stack

TB-500 is a fragment, not full-length thymosin beta-4; evidence does not transfer automatically.

mostly mechanism

503A review only; highest risk

N/A

Semaglutide / tirzepatide

Compounded access during shortage or affordability constraints

A compounded product may contain a studied molecule, but source, concentration, sterility, and labeling add separate risks.

framework row

Shortage compounding; varies

Retatrutide

Weight loss / metabolic pipeline drug

Retatrutide has human trial data; until approval, access belongs in a clinical trial.

credible human signal

Investigational; moderate risk

Retatrutide

Research-use or gray-market retatrutide

Retatrutide trial results do not validate a research vial bought online.

claim outruns evidence

Gray-market; highest risk

Semaglutide / tirzepatide

Research-use or gray-market GLP-1 products

Approved-drug evidence does not validate a research or gray-market GLP-1 product.

claim outruns evidence

Gray-market; highest risk

Semaglutide salt forms

Semaglutide sodium/acetate is basically the same

Semaglutide sodium and acetate are not the active ingredient used in FDA-approved semaglutide products.

claim outruns evidence

Gray-market; highest risk

All Decoder rows

The live table includes only rows that passed final source review.

Grade	Peptide	Claim	Evidence	Access	First move
A	DEC-001 Semaglutide / tirzepatide Related guide	Summary anchor: weight loss, diabetes, cardiometabolic risk Semaglutide and tirzepatide have FDA-approved uses backed by large human trials. That evidence applies to the indicated drug and product, not every peptide vial.	Large human RCTs and FDA-approved indications; outcomes vary by drug and indication.	FDA-approved drugs for specific indications FDA-approved branded; lower risk	Standard obesity/diabetes/cardiometabolic care
D	DEC-003 BPC-157 Guide planned	Injury recovery, tendon/ligament healing, joint pain, gut repair BPC-157 has animal data and one tiny uncontrolled human series; that cannot guide recovery or return to sport.	Animal and laboratory studies make up most of the evidence. One tiny uncontrolled human series reported knee-pain outcomes. NCT07437547 is recruiting for acute hamstring strain and has posted no results.	Not FDA-approved; FDA staff recommended against 503A listing; PCAC voted 8-6-1 per form in favor; FDA has not issued a final rule 503A review only; highest risk	Diagnosis, load management, progressive rehab, imaging when indicated, evidence-based sports medicine
D	DEC-004 TB-500 / thymosin beta-4 fragment Guide planned	Injury recovery, tendon/muscle healing, Wolverine stack TB-500 is a fragment, not full-length thymosin beta-4; evidence does not transfer automatically.	NCT07487363 is recruiting and has no posted results. Full-length thymosin beta-4 evidence is adjacent, not direct evidence for the TB-500 fragment.	Not FDA-approved; FDA staff recommended against 503A listing; PCAC voted 8-6-1 per form in favor; FDA has not issued a final rule 503A review only; highest risk	Diagnosis, rehab, objective return-to-play criteria
D	DEC-005 KPV Guide planned	Gut inflammation, IBD-style claims, eczema/psoriasis/acne, systemic inflammation KPV has promising preclinical biology but no direct human drug-exposure data.	FDA identified no direct human exposure to KPV drug products by any route; the evidence remains preclinical gut and skin models.	Not FDA-approved; FDA staff recommended against 503A listing; PCAC voted 8-6-1 per form in favor; FDA has not issued a final rule 503A review only; high risk	Standard GI/dermatology workup and evidence-based anti-inflammatory care
D	DEC-006 MOTS-c Guide planned	Metabolic flexibility, insulin sensitivity, exercise-mimetic effects MOTS-c has not yet shown improved patient outcomes.	NCT07505745 is recruiting and has no posted outcomes. CB4211 is an analog, not direct evidence for administered MOTS-c.	Not FDA-approved; FDA staff recommended against 503A listing; PCAC voted 7-5-2 per form in favor; FDA has not issued a final rule 503A review only; high risk	Exercise, nutrition, sleep, GLP-1/GIP care when clinically indicated, metabolic workup
D	DEC-007 MOTS-c Guide planned	Weight loss or GLP-1 alternative MOTS-c is not an evidence-based GLP-1 alternative.	No convincing human weight-loss outcome evidence; NCT07505745 is recruiting without results, and CB4211 is an analog rather than direct MOTS-c evidence.	Not FDA-approved; FDA staff recommended against 503A listing; PCAC voted 7-5-2 per form in favor; FDA has not issued a final rule 503A review only; high risk	Evidence-based obesity care, GLP-1/GIP agents when appropriate
D	DEC-008 Emideltide / DSIP Guide planned	Sleep depth, chronic insomnia, stress/HPA axis Small, old, mixed studies do not support DSIP for chronic insomnia.	Small, old human sleep studies produced mixed results, and researchers have not replicated them in a modern chronic-insomnia trial.	Not FDA-approved; FDA staff recommended against 503A listing; PCAC voted 6-7-1 per form against; FDA has not issued a final rule 503A review only; high risk	CBT-I, sleep apnea screen, behavioral sleep treatment, clinically appropriate medications
D	DEC-009 Emideltide / DSIP Guide planned	Opioid withdrawal, pain, mood/cortisol support One old uncontrolled report does not establish addiction, pain, or mood care.	An old uncontrolled withdrawal report and tiny mixed sleep studies do not establish modern addiction, pain, or mood care.	Not FDA-approved; FDA staff recommended against 503A listing; PCAC voted 6-7-1 per form against; FDA has not issued a final rule 503A review only; high risk	Evidence-based addiction medicine, pain evaluation, sleep and mental-health care
C	DEC-010 Semax Guide planned	Stroke/cerebrovascular recovery Semax has a limited human stroke signal but no modern replicated evidence or US approval.	One older 110-person post-stroke study reported a signal, but modern multicenter studies have not independently replicated it.	Not FDA-approved in the US; FDA staff recommended against 503A listing; PCAC voted 8-5-1 per form in favor; FDA has not issued a final rule 503A review only; high risk	Standard acute stroke and rehab care; neurology-guided treatment
D	DEC-011 Semax Guide planned	Focus, ADHD, nootropic, brain fog, productivity A post-stroke study does not prove benefits for focus, ADHD, or brain fog.	The older 110-person post-stroke signal does not establish focus, ADHD, brain-fog, or healthy-person productivity benefits.	Not FDA-approved in the US; FDA staff recommended against 503A listing; PCAC voted 8-5-1 per form in favor; FDA has not issued a final rule 503A review only; high risk	ADHD evaluation, sleep, mood, iron/B12/thyroid where appropriate, evidence-based stimulants/nonstimulants when indicated
D	DEC-012 Epitalon Guide planned	Circadian/longevity/telomere biology Cell and animal findings cannot establish whether epitalon extends human life.	Synthetic epitalon is distinct from epithalamin; cell, animal, and epithalamin findings do not establish human longevity outcomes for epitalon.	Not FDA-approved; FDA staff recommended against 503A listing; PCAC voted 7-4-1 per form in favor; FDA has not issued a final rule 503A review only; high risk	Sleep/circadian basics, light timing, exercise, metabolic and cardiovascular prevention
F	DEC-013 Epitalon Guide planned	Insomnia treatment No controlled trial supports synthetic epitalon for insomnia.	No controlled trial supports synthetic epitalon for insomnia. Studies of epithalamin do not establish effects for synthetic epitalon.	Not FDA-approved; FDA staff recommended against 503A listing; PCAC voted 7-4-1 per form in favor; FDA has not issued a final rule 503A review only; high risk	CBT-I, sleep apnea screen, circadian rhythm workup, evidence-based insomnia care
N/A	DEC-014 Peptide COA Guide planned	99% pure means safe A COA may support identity or purity; it cannot prove sterility, correct concentration, or injection safety.	Quality-literacy framework, not efficacy evidence.	COA varies by vendor/lab and does not establish clinical appropriateness Framework; varies	Regulated pharmacy supply, sterile compounding standards, clinician oversight
N/A	DEC-015 FDA / 503A status Guide planned	If a clinic can get it, it must be proven A clinic's ability to obtain a peptide does not prove that it works.	Regulatory-literacy framework based on FDA/PCAC materials.	503A/PCAC review is not approval or efficacy evidence Framework; not a route claim	FDA-approved drug pathway, clinical trials, supervised care
N/A	DEC-038 Semaglutide / tirzepatide Guide planned	Compounded access during shortage or affordability constraints A compounded product may contain a studied molecule, but source, concentration, sterility, and labeling add separate risks.	This row addresses access and product quality rather than efficacy.	503A/503B/shortage-dependent access category, source must be verified at time of writing Shortage compounding; varies	FDA-approved branded supply when accessible; clinician/pharmacy due diligence if compounded
B	DEC-039 Retatrutide Guide planned	Weight loss / metabolic pipeline drug Retatrutide has human trial data; until approval, access belongs in a clinical trial.	Human trials show promising weight and metabolic effects. FDA has not approved retatrutide.	Investigational drug category, not gray-market wellness access Investigational; moderate risk	Approved obesity medications or clinical trial enrollment
F	DEC-040 Retatrutide Guide planned	Research-use or gray-market retatrutide Retatrutide trial results do not validate a research vial bought online.	Results from regulated clinical trials do not establish the identity, concentration, sterility, or safety of non-prescribed supply.	Research-use/gray-market access Gray-market; highest risk	Do not self-source; consider approved options or clinical trials
F	DEC-041 Semaglutide / tirzepatide Guide planned	Research-use or gray-market GLP-1 products Approved-drug evidence does not validate a research or gray-market GLP-1 product.	Approved-drug evidence does not validate non-prescribed supply, concentration, sterility, or labeling.	Gray-market/research-use access Gray-market; highest risk	FDA-approved branded supply when accessible; clinician/pharmacy due diligence if compounded
F	DEC-042 Semaglutide salt forms Guide planned	Semaglutide sodium/acetate is basically the same Semaglutide sodium and acetate are not the active ingredient used in FDA-approved semaglutide products.	FDA states salt forms such as semaglutide sodium and semaglutide acetate are different active ingredients than approved semaglutide products and should not be used for compounding.	Unapproved/salt-form access problem Gray-market; highest risk	Avoid salt-form substitutions; use approved or appropriately supervised regulated pathways
B	DEC-043 Retatrutide Guide planned	Type 2 diabetes / glycemic control Strong trial data can precede approval; they do not create retail access.	Phase 2 and phase 3 human trials support glycemic and weight effects, but regulatory approval/access status remains separate.	Investigational drug category, not approved access Investigational; moderate risk	Approved diabetes/obesity medications or clinical trial enrollment
B	DEC-044 Retatrutide Guide planned	MASLD / liver fat reduction MRI data show less liver fat; they do not yet prove MASH, fibrosis, or longevity benefit.	A Phase 2a substudy found substantial liver-fat reduction by MRI-PDFF. It did not establish a biopsy-proven MASH or fibrosis outcome or a longevity benefit.	Investigational drug category, not approved access Investigational; moderate risk	MASLD workup, weight-loss therapy, cardiometabolic risk management, clinical trial enrollment
F	DEC-045 AOD-9604 Guide planned	Weight loss and fat loss AOD-9604 failed to beat placebo for weight loss in most studies FDA reviewed.	FDA's 2024 review reported that AOD-9604 failed to reduce weight versus placebo in most of the studies it assessed.	Not FDA-approved; FDA staff recommended against 503A listing; PCAC voted 0-12-0 on the combined free-base and acetate forms in December 2024; FDA has not issued a final rule 503A review only; highest risk	Evidence-based obesity care and approved weight-management treatment when appropriate

DEC-001

Semaglutide / tirzepatide

Summary anchor: weight loss, diabetes, cardiometabolic risk

Semaglutide and tirzepatide have FDA-approved uses backed by large human trials. That evidence applies to the indicated drug and product, not every peptide vial.

Evidence: Large human RCTs and FDA-approved indications; outcomes vary by drug and indication.
Access: FDA-approved drugs for specific indications
First move: Standard obesity/diabetes/cardiometabolic care

FDA-approved branded; lower risk · Related guide

DEC-003

BPC-157

Injury recovery, tendon/ligament healing, joint pain, gut repair

BPC-157 has animal data and one tiny uncontrolled human series; that cannot guide recovery or return to sport.

Evidence: Animal and laboratory studies make up most of the evidence. One tiny uncontrolled human series reported knee-pain outcomes. NCT07437547 is recruiting for acute hamstring strain and has posted no results.
Access: Not FDA-approved; FDA staff recommended against 503A listing; PCAC voted 8-6-1 per form in favor; FDA has not issued a final rule
First move: Diagnosis, load management, progressive rehab, imaging when indicated, evidence-based sports medicine

503A review only; highest risk · Guide planned

DEC-004

TB-500 / thymosin beta-4 fragment

Injury recovery, tendon/muscle healing, Wolverine stack

TB-500 is a fragment, not full-length thymosin beta-4; evidence does not transfer automatically.

Evidence: NCT07487363 is recruiting and has no posted results. Full-length thymosin beta-4 evidence is adjacent, not direct evidence for the TB-500 fragment.
Access: Not FDA-approved; FDA staff recommended against 503A listing; PCAC voted 8-6-1 per form in favor; FDA has not issued a final rule
First move: Diagnosis, rehab, objective return-to-play criteria

503A review only; highest risk · Guide planned

DEC-005